Halozyme Q4 revenue up 78% to $181M; 2023 guidance $815-845M

HALOZYME THERAPEUTICS, INC.

2022-FY EPS reported $1.44 revenue$660,116,000

Q4 revenue $181M (+78% YoY); full-year revenue $660.1M (+49% YoY).
Q4 GAAP diluted EPS $0.42; non-GAAP diluted EPS $0.48. Full-year GAAP EPS $1.44; non-GAAP EPS $2.21.
Record Q4 royalty revenue $106M (+69% YoY); full-year royalties $360.5M (+77% YoY).
2023 guidance: revenue $815-845M (23-28% growth), EBITDA $415-440M (>30% growth), non-GAAP EPS $2.50-2.65.
Completed $110M ASR; $350M of $750M buyback executed; elected Barbara Duncan to board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. reported the full year ended December 31, 2022 results: revenue $660.1 million, EPS $1.44 per diluted share.

Period: the full year ended December 31, 2022
Revenue: $660.1 million
EPS: $1.44 per diluted share
Result: reported results

Exact text from the filing

Full Year 2022 Revenue Increased 49% YOY to $660.1 million; GAAP Diluted Earnings per Share of $1.44 and Non-GAAP Diluted Earnings per Share of $2.21

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. reported 2023 results: revenue $815 million to $845 million. Guidance initiated.

Period: 2023
Revenue: $815 million to $845 million
Guidance: initiated
Result: guidance update

Exact text from the filing

2023 Revenue Guidance of $815 million to $845 million, Representing 23%-28% YOY Growth; EBITDA of $415 million to $440 million, Representing >30% YOY Growth

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $181 million, EPS $0.42 per diluted share.

Period: the fourth quarter ended December 31, 2022
Revenue: $181 million
EPS: $0.42 per diluted share
Result: reported results

Exact text from the filing

Fourth Quarter Revenue Increased 78% YOY to $181 million; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.48

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-23-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.